Patent Expiration of Recombinant Protein Products
Regulatory Topics on Follow-on Biologics
• Guidelines on similar biological medicinal products had been developed in EU.
• Biosimilar products of recombinant human growth hormone, erythropoietin, or G-CSF were approved in EU.
• Expert meeting on international nonproprietary names of follow-on biologics was held in WHO.（Sep. 2006,Nov. 2006）
• Expert meeting on WHO guidelines for the abbreviated licensing pathways for biological therapeutic products was held.（Apr. 2007）
• Guidance on follow-on protein products has not been published from FDA. Product-related substances ・deamidated products ・oxidized products ・N/C terminal deleted products
Immunogenicity Issues in Development of Follow-on Biologics
• In clinical studies with the earlier formulation of Omnitrope, up to 60% of the enrolled patients developed anti-hGH antibodies and all patients developed anti-ECP antibodies.
• ECP are known to be able to enhance the antibody reaction against GH.
• Downstream manufacturing process was modified to improve the ECP clearance.
Omnitrope: EPAR summary for the public 
Identity of Cell Substrates
Adhesive cells Suspension cells Serum-free media adapted cells
• Published information is not enough to identify the exactly same cell line / strain as that used for the production of the reference product.
• Optimum media differ depends on the strains.
• Cellular characteristics may be modified by adapting cells to serum free and/or suspension culture during the process development stage.
• "CHO cell" has several strains.
-CHO-K1 -CHO-DUKX -CHO-DG44 -CHO-Pro5 
• Approaches to evaluate the comparability between reference products and follow-on products
• Comparability studies： -Availability of reference products (Drug substance may not be available.） -Studies using drug product • 2007 Discussion group for the guideline on follow-on biologics was established.
• 2008 Draft guideline was developed.
• Sep. 2008 The draft guideline was released for public comments.
• 2009 The final guideline is under construction with considering the comments from the public.
Japanese Guideline on Follow-on Biologics
• The guideline covers from establishment of production process to non-clinical/clinical studies.
• Ten to fifteen years scientific progress after the approval of the innovator's products should be considered in evaluating the product characteristics.
• Theoretically all kinds of follow-on biologics can be developed, however, the guideline deals with recombinant protein products in which the definition of desired product is clear, and the approach for characterization is relatively easy. 1. Introduction A "Follow-on biologics" is intend to refer a biotechnological product that is produced by a subsequent-entry manufacturer and claimed to be comparable to a biotechnological product already approved in Japan (hereinafter "reference medicinal product").
A new Marketing Authorization Application（MAA） category different from the existing generic approach should be established.
It is recommended to adopt the manufacturing processes which potentially improve safety of the product.
Scope
The guideline applies to recombinant proteins and polypeptides, their derivatives, and products of which they are components, (e.g., conjugates).
These proteins and polypeptides are produced from recombinant cell-culture expression systems and can be highly purified and characterized using an appropriate set of analytical procedures.
Decision Products Reasons Notes

Recombinant plasma proteins
There is no reason to exclude recombinant plasma proteins from the scope, although some proteins have highly complicated structure.
Some patients might prefer nonrecombinant products. Blood product supply might be affected, although overlapped product development ensures the consistent supply.
Recombinant vaccines
Well characterized recombinant vaccine can be possibly developed as follow-on biologics.
Vaccine is administrated to healthy humans. Lot-to-lot variation of adjuvant activity is relatively large.
PEGylated recombinant proteins
Conjugates are in the scope as is in ICH Q6B.
Development of PEGylated protein as follow-on biologics might be difficult due to the structural complexity.
Synthetic peptides
Impurity profile is different from that of recombinant proteins.
Synthetic peptides can be generic drugs, because desired product can be easily defined by structural analyses.
Polyglycans
Characterization is difficult. Several polyglycan products have been approved as generic drugs in Japan.
Case by case
Nonrecombinant proteins* Proteins that are highly purified and characterized could be developed as follow-on biologics.
Several urine-derived protein products have been approved as generic drugs in Japan.
No
Yes
Discussion on the scope of the guideline * e.g. proteins such as isolated from tissues or body fluids 3. General Principles for the Development of Follow-on Biologics (1)
As with new biotechnological products, establishment of the well-defined manufacturing process, and extensive characterization studies to reveal the molecular and quality attributes of the follow-on biologics are required.
Demonstration of the high similarity in quality attributes with the reference medicinal product is also required.
Comparability between the follow-on biologics and reference medicinal product should be evaluated based on the data from non-clinical and clinical studies in addition to the data of quality characteristics.
